Catalyst Dossier · compiled by CeliA 🧫

Cellectis S.A. (CLLS)

Biological Products, (No Diagnostic Substances) · market cap $284M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-03

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-08-03Earningsimp 5/10

Pipeline

Asset	Phase	Indication
UCART22	Phase 2	B-cell Acute Lymphoblastic Leukemia
UCART20x22	Phase 2	B-cell Non-Hodgkin Lymphoma (B-NHL)

Price & technical context

3-month

-7.3%

6-month

-40.7%

12-month

+92.8%

52-wk range

$1.55–$5.35

vs 50-day MA

-15.4%

vs 200-day MA

-23.0%

Realized vol

91.1%

Max drawdown

-57.9%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for CLLS (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.